A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS) by Marlies Ostermann, David C. Corteville, Kent Doi, Jay L. Koyner, Andre Lamy, Gerry Li, Christine M. Solinsky, Pamela D. Winterberg, William T. Smith, Ravindra L. Mehta, Patrick T. Murray, Andrew D. Shaw, Alexander Zarbock, Daniel T. Engelman

Get full text